July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Topical treatment for AMD: Non-invasive delivery and efficacy of ranibizumab and bevacizumab in rabbit and porcine eyes
Author Affiliations & Notes
  • Felicity De Cogan
    Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
  • Aisling Lynch
    Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
  • Matthew Berwick
    University Hospital Coventry, Coventry, United Kingdom
  • Anna Peacock
    University of Birmingham, Birmingham, United Kingdom
  • Samer Elsherbiny
    Warwick Hospital, Warwick, United Kingdom
  • Heping Xu
    Queens University Belfast, Belfast, United Kingdom
  • Mei Chen
    Queens University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships   Felicity De Cogan, University of Birmingham (P); Aisling Lynch, None; Matthew Berwick, None; Anna Peacock, University of Birmingham (P); Samer Elsherbiny, None; Heping Xu, None; Mei Chen, None
  • Footnotes
    Support  Wellcome Trust 109674/Z/15/Z
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1439. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Felicity De Cogan, Aisling Lynch, Matthew Berwick, Anna Peacock, Samer Elsherbiny, Heping Xu, Mei Chen; Topical treatment for AMD: Non-invasive delivery and efficacy of ranibizumab and bevacizumab in rabbit and porcine eyes. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1439.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate cell penetrating peptides (CPP) as novel topical ocular drug delivery vehicles. To use the CPP to replace intravitreal injections that transport anti-VEGF therapeutics, into the posterior segment of rabbit and pig eyes with CPP mediated topical delivery.

Methods : Delivery of ranibizumab and bevacizumab to the posterior segment by the CPP eye drop was determined in rabbit eyes in vivo and porcine eyes ex vivo using ELISA. CPPs were mixed with anti-VEGF and their efficacy was tested using an established model of choridal neovascularization. Animals were then treated with i) CPP+anti-VEGF eye drop, ii) anti-VEGF eye drop, iii) CPP eye drop, v) anti-VEGF intravitreal injection (ivit), vi) saline eye drop. Outcomes were measured using in vivo retinal imaging and immunohistochemistry.

Results : After topical delivery in porcine eyes the CPP+ranibizumab eye drop delivered 1.7±0.4 µg/mL and the CPP+bevacizumab eye drop delivered 1.1±0.3µg/mL all significantly higher levels (p<0.005) than CPP, saline, ranibizumab or bevacizumab alone. In rabbits, CPP+bevacizumab eye drop delivered 4.0±2.3 µg/retina at 24 hours significantly higher than controls (p<0.05). This increased over 3 days to 83.31±39.72 µg/retina and cleared from the retina over 7 days. Efficacy in disease models was determined in rodents using established models of neovascularization. Animals which had an anti-VEGF ivit and CPP+anti-VEGF eye drop had significantly lower (p<0.05) areas of neovascularization than eyes with no treatment, anti-VEGF eye drop, CPP eye drop and PBS eye drop all of which were not significantly different from the untreated eyes.

Conclusions : CPP can be used to deliver both ranibizumab and bevacizumab to the posterior segment of the eye in rabbit and pig eyes. The CPP delivered bevacizumab gave a 7 day clearance pattern in rabbits suggesting a weekly dosing regimen. The CPP delivered anti-VEGF showed efficacy in a disease model of neovascularization with no significant differences between intravitreally injected anti-VEGF and CPP topically delivered anti-VEGF.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×